Is Sorafenib/Nexavar a targeted therapy drug?

Sorafenib/Nexavar (Sorafenib) is indeed a targeted therapy drug. It is a multi-target tyrosine kinase inhibitor that is widely used to treat a variety of advanced solid tumors. It was first approved for the treatment of inoperable advanced liver cancer (HCC) and was subsequently used to treat advanced renal cell carcinoma (RCC) and thyroid cancer. The targeting mechanism of sorafenib is mainly by inhibiting multiple key signaling pathways involved in tumor cell proliferation and tumor angiogenesis, including the Raf/MEK/ERK pathway, as well as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), etc. This "multi-pathway, multi-target" inhibition mechanism not only inhibits the growth of tumor cells, but also blocks the formation of tumor blood vessels, thereby achieving the purpose of anti-cancer.

The biggest difference between targeted therapy and traditional chemotherapy is that it generally has greater selectivity and lower systemic toxicity by specifically recognizing and inhibiting the unique molecular mechanisms of cancer cells. Although sorafenib is a targeted drug, its side effects cannot be ignored, such as skin reactions (hand-foot syndrome), hypertension, diarrhea, fatigue, etc. Some patients may also experience abnormal liver function. In clinical application, it is necessary to closely monitor the patient's tolerance, adjust the dose or carry out symptomatic treatment according to adverse reactions.

The emergence of sorafenib marks the entry into the targeted era of systemic treatment of liver cancer, and also brings new hope to advanced patients who are inoperable or have failed local treatment. Although with the emergence of immunotherapy and newer generations of targeted drugs, sorafenib is no longer the first choice in some indications, it is still one of the important treatment options for many patients. In actual treatment, whether to use sorafenib needs to be comprehensively judged based on the patient's specific condition, genetic background, and tolerance.

Reference materials:https://www.nexavar.com/